biologic

Xembify

immune globulin subcutaneous, human-klhw

Loss of exclusivityJuly 2031projected — 12-year biologic exclusivity estimate
CompanyGrifolsView the full company profile on CliffBio

Drug detail

Brand nameXembify
Active ingredientimmune globulin subcutaneous, human-klhw
Strength10GM MG/ML
Dosage formInjection
RouteSubcutaneous
ModalityBiologic
FDA approvalJuly 2019
Marketing statusRx

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the projected — 12-year biologic exclusivity estimate; estimates are projections, not legal advice.

Xembify patent cliff — loss of exclusivity July 2031 | CliffBio